Product Overview

Lamivir S 40 mg is a fixed‑dose combination tablet manufactured by Cipla Limited, a globally recognized pharmaceutical company with a strong track record in antiretroviral production. Each tablet contains 300 mg of lamivudine (also known as 3TC) and 40 mg of stavudine (d4T), two nucleoside reverse transcriptase inhibitors that work synergistically to suppress HIV‑1 replication. The medication is supplied in sealed bottles, each holding 60 tablets, and the company offers value packs of 120 and 180 tablets for patients who require long‑term therapy. Shipping times range from six to fifteen days, allowing patients in various regions to receive a reliable supply without interruption. This product is specifically indicated for the treatment of HIV infection in adults who are treatment‑naïve or have previously used other antiretroviral regimens. The formulation is intended for oral administration and should be stored at room temperature, away from moisture and direct sunlight.

What is Lamivir S 40 mg?

Lamivir S belongs to the class of nucleoside reverse transcriptase inhibitors (NRTIs), a cornerstone of modern HIV combination therapy. Lamivudine functions as a thymidine analog that, once phosphorylated inside infected cells, incorporates into the growing viral DNA strand and prevents its further extension, effectively halting reverse transcription. Stavudine, a dideoxynucleoside, also undergoes phosphorylation to its active triphosphate form, which serves as a substrate for the viral reverse transcriptase but lacks the necessary 3’‑hydroxyl group, leading to premature chain termination. The combination of these two agents provides complementary mechanisms of action, reducing the likelihood of viral resistance emergence. Clinical pharmacology studies cited by the NIH demonstrate that the fixed‑dose combination achieves consistent plasma concentrations of both active ingredients, supporting sustained viral suppression when used as part of a complete antiretroviral regimen.

Uses and Benefits

The primary therapeutic use of Lamivir S 40 mg is as part of a combination antiretroviral regimen for the treatment of HIV‑1 infection in adults. By effectively lowering viral load, the medication helps preserve CD4⁺ T‑cell counts and delays the progression to AIDS‑defining illnesses. Large cohort studies referenced by the CDC show that regimens containing lamivudine/stavudine achieve undetectable viral levels in more than 80 % of patients after 48 weeks of continuous use. In addition to virologic benefits, patients often experience improved energy levels, reduced frequency of opportunistic infections, and an overall better quality of life. The fixed‑dose formulation simplifies dosing schedules, enhances adherence, and minimizes the pill burden compared with using separate tablets, which can be particularly advantageous for patients with busy lifestyles or those who travel frequently.

How It Works

The antiviral activity of Lamivir S stems from the dual inhibition of HIV‑1 reverse transcriptase, the enzyme responsible for converting viral RNA into DNA. Lamivudine, after intracellular activation to its triphosphate form, mimics the natural substrate deoxythymidine and is incorporated into the nascent viral DNA chain; its structural modification prevents the DNA polymerase from adding further nucleotides, causing chain termination. Stavudine, once phosphorylated to stavudine‑triphosphate, acts as a chain terminator by lacking a 3’‑hydroxyl group, thereby halting DNA elongation. The synergistic effect of these mechanisms not only suppresses viral replication more efficiently but also reduces the selective pressure that drives resistance development. Detailed pharmacokinetic data are available through the NIH book which outlines absorption, distribution, metabolism, and excretion profiles for both components.

Dosage Guidelines

Adult patients are generally prescribed one Lamivir S 40 mg tablet taken orally once daily, with or without food, to maintain consistent drug levels. In individuals with impaired renal function, defined as a creatinine clearance below 30 mL/min, dose reduction is recommended, or alternative dosing schedules may be employed under medical supervision. If a dose is missed, the patient should take it as soon as remembered provided there is a sufficient interval before the next scheduled dose; otherwise, the missed dose should be skipped to avoid double dosing. Pediatric patients receive weight‑based dosing that must be calculated by a qualified healthcare professional, and the formulation is not recommended for children under a certain age unless specifically indicated. It is essential to adhere strictly to the prescribed regimen and to undergo regular laboratory monitoring, including assessment of liver enzymes and renal function, to ensure safety and efficacy throughout treatment.

Side Effects

Like all antiretroviral medications, Lamivir S can produce adverse effects, ranging from mild to serious. The most frequently reported side effects include gastrointestinal symptoms such as nausea, vomiting, and abdominal discomfort, as well as central nervous system complaints like headache and insomnia. Stavudine is particularly associated with peripheral neuropathy, manifesting as tingling, burning, or numbness in the hands and feet; this risk increases with higher cumulative doses. Although rare, serious metabolic disturbances such as lactic acidosis, severe hepatomegaly, and pancreatitis have been documented, necessitating immediate medical evaluation if patients develop unexplained muscle pain, rapid breathing, or severe abdominal distress. Routine laboratory monitoring of hepatic transaminases, serum amylase, and renal parameters is recommended, especially during the first six months of therapy.

Warnings and Precautions

Patients should be aware of several important warnings before initiating Lamivir S therapy. The medication is contraindicated in individuals with a known hypersensitivity to lamivudine, stavudine, or any excipients present in the tablet formulation. Caution is advised in patients with pre‑existing hepatic disease, as dose adjustments may be required to prevent further liver injury. Pregnant women should use the drug only when the anticipated benefit justifies the potential risk, as stavudine has been classified by the FDA as a category C medication; breastfeeding is generally discouraged due to the possibility of viral transmission. Proper storage conditions—room temperature, protected from moisture and heat—are essential to maintain potency. Additionally, clinicians should review a patient’s complete medication list to identify potential drug‑interactions, particularly with other nucleoside analogs or agents that affect mitochondrial function. For full safety information, see the FDA label.

Frequently Asked Questions

1. What is Lamivir S 40 mg used for?
   Lamivir S 40 mg is indicated for the treatment of HIV‑1 infection in adults, and it is used as part of a combination antiretroviral regimen to suppress viral replication, preserve CD4 cell counts, and reduce the risk of disease progression.
2. How should I take Lamivir S?
   The recommended adult dose is one tablet taken once daily, with or without food. If a dose is missed, take it as soon as you remember unless it is close to the time of the next dose; in that case, skip the missed dose and continue with your regular schedule. Always follow the dosing instructions provided by your healthcare provider.
3. Can Lamivir S be taken with other HIV medicines?
   Yes, Lamivir S is frequently combined with other antiretroviral agents such as protease inhibitors or additional NRTIs to create a complete regimen. However, a thorough drug‑interaction review is essential, and any changes to the regimen should be supervised by a qualified clinician.
4. What should I do if I experience side effects?
   Most side effects are mild and may resolve on their own, but if you develop severe symptoms such as persistent nausea, neuropathy, muscle pain, or signs of liver problems (e.g., yellowing of the skin or eyes), you should contact your physician immediately. Regular laboratory monitoring helps detect adverse events early.
5. Are there any dietary restrictions while using Lamivir S?
   No specific dietary restrictions are required; the tablet can be taken with or without food. However, patients should maintain adequate hydration and avoid excessive alcohol consumption, which can increase the risk of liver toxicity.

Related Products

• Ciplox 750mg (Ciprofloxacin)
• Diclofenac SR 100 mg
• Reactin 50 mg (Diclofenac)
• Cromal Forte Eye Drop (Sodium Cromoglycate)
• Alendronic Acid 35 mg (Generic)
• Rizact 5 mg (Rizatriptan)
• Flunarizine 5 mg (Generic)
• Warf 1 mg (Warfarin)
• Warf 2 mg (Warfarin)
• Warf 3 mg (Warfarin)
• Mucinac 200 mg (Acetylcysteine)
• Temozolomide 20 mg (Generic)